Brynjelsen Sean's Form 4 filing
Eton Pharmaceuticals, Inc.ETON · filed May 29, 2026
- Accession no.
- 0001437749-26-018879
- Filed
- May 29, 2026
- Trade date
- May 28, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $3.83M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Brynjelsen SeanCIK 0001669976 | Director, Officer (President & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The shares were sold in multiple trades at prices ranging from $31.59 to $32.55. The price above reflects the weighted average sales price.
Referenced by the price of 1 transaction in Table I.
- F2
The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.